Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.

Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C, Marchetti S, Hamouda MA, Boulakirba S, Orange F, Lacas-Gervais S, Karsenti JM, Mounier N, Tamburini J, Puissant A, Luciano F, Jacquel A, Auberger P, Robert G.

Leukemia. 2019 Jun;33(6):1501-1513. doi: 10.1038/s41375-018-0336-1. Epub 2019 Jan 3.

PMID:
30607021
2.

HER2 Signaling Hijacks the Creatine Shuttle to Fuel Breast Cancer Cell Growth.

Ben-Sahra I, Puissant A.

Cell Metab. 2018 Dec 4;28(6):805-807. doi: 10.1016/j.cmet.2018.11.009.

PMID:
30517893
3.

Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.

Benajiba L, Alexe G, Su A, Raffoux E, Soulier J, Hemann MT, Hermine O, Itzykson R, Stegmaier K, Puissant A.

Leukemia. 2019 Mar;33(3):800-804. doi: 10.1038/s41375-018-0291-x. Epub 2018 Nov 2. No abstract available.

PMID:
30390009
4.

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.

Ali A, Penneroux J, Dal Bello R Jr, Massé A, Quentin S, Unnikrishnan A, Hernandez L, Raffoux E, Ben Abdelali R, Renneville A, Preudhomme C, Pimanda J, Dombret H, Soulier J, Fenaux P, Clappier E, Adès L, Puissant A, Itzykson R.

Leukemia. 2018 Aug;32(8):1856-1860. doi: 10.1038/s41375-018-0076-2. Epub 2018 Feb 26. No abstract available.

PMID:
29535430
5.

Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.

Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, Kaya T, Shi X, Robers MB, Machleidt T, Wilkinson J, Hermine O, Kung A, Stein AJ, Lakshminarasimhan D, Hemann MT, Scolnick E, Zhang YL, Pan JQ, Stegmaier K, Holson EB.

Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460. doi: 10.1126/scitranslmed.aam8460.

6.

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.

Weisberg EL, Puissant A, Stone R, Sattler M, Buhrlage SJ, Yang J, Manley PW, Meng C, Buonopane M, Daley JF, Lazo S, Wright R, Weinstock DM, Christie AL, Stegmaier K, Griffin JD.

Oncotarget. 2017 Jul 6;8(32):52026-52044. doi: 10.18632/oncotarget.19036. eCollection 2017 Aug 8.

7.

[Autophagy, a key player in leukemogenesis and a therapeutic target in hematopoietic malignancies].

Jacquel A, Luciano F, Puissant A, Robert G, Auberger P.

Med Sci (Paris). 2017 Mar;33(3):226-229. doi: 10.1051/medsci/20173303007. Epub 2017 Apr 3. French. No abstract available.

8.

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K.

Nat Med. 2017 Mar;23(3):301-313. doi: 10.1038/nm.4283. Epub 2017 Feb 13.

9.

Autophagy, a key mechanism of oncogenesis and resistance in leukemia.

Auberger P, Puissant A.

Blood. 2017 Feb 2;129(5):547-552. doi: 10.1182/blood-2016-07-692707. Epub 2016 Dec 12. Review.

10.

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F.

J Exp Med. 2016 Aug 22;213(9):1705-22. doi: 10.1084/jem.20150983. Epub 2016 Jul 25.

11.

Targeting MTHFD2 in acute myeloid leukemia.

Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K.

J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20.

12.

Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.

Boros K, Puissant A, Back M, Alexe G, Bassil CF, Sinha P, Tholouli E, Stegmaier K, Byers RJ, Rodig SJ.

Oncotarget. 2015 Sep 22;6(28):25575-87. doi: 10.18632/oncotarget.4669.

13.

The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.

Hamouda MA, Belhacene N, Puissant A, Colosetti P, Robert G, Jacquel A, Mari B, Auberger P, Luciano F.

Oncotarget. 2014 Aug 15;5(15):6252-66.

14.

SYK is a critical regulator of FLT3 in acute myeloid leukemia.

Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, Hemann MT, Stegmaier K.

Cancer Cell. 2014 Feb 10;25(2):226-42. doi: 10.1016/j.ccr.2014.01.022.

15.

MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Liu S, Yin L, Stroopinsky D, Rajabi H, Puissant A, Stegmaier K, Avigan D, Kharbanda S, Kufe D, Stone R.

Blood. 2014 Jan 30;123(5):734-42. doi: 10.1182/blood-2013-04-493858. Epub 2013 Nov 26.

16.

Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties.

Bertero T, Bourget-Ponzio I, Puissant A, Loubat A, Mari B, Meneguzzi G, Auberger P, Barbry P, Ponzio G, Rezzonico R.

Cell Cycle. 2013 Jul 15;12(14):2183-93. doi: 10.4161/cc.25330.

17.

In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling.

Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, Fujisaki J, Silberstein L, Alexe G, Al-Hajj MA, Shelton CA, Armstrong SA, Root DE, Scadden DT, Hynes RO, Mukherjee S, Stegmaier K, Jordan CT, Ebert BL.

Cancer Cell. 2013 Jul 8;24(1):45-58. doi: 10.1016/j.ccr.2013.05.004. Epub 2013 Jun 13.

18.

Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K.

Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.

19.

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.

Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.

Oncotarget. 2012 Dec;3(12):1557-65.

20.

When autophagy meets cancer through p62/SQSTM1.

Puissant A, Fenouille N, Auberger P.

Am J Cancer Res. 2012;2(4):397-413. Epub 2012 Jun 28.

Supplemental Content

Loading ...
Support Center